What is the clinical evidence from this study?

Study design: RCT. Population: Postoperative nausea and vomiting (n=50). Intervention: Ondansetron vs. Placebo. Primary outcome: Complete responders (no emetic episodes and no rescue therapy) (p=<0.001).

What does this research mean for the field?

Intravenous ondansetron significantly reduces postoperative nausea and vomiting compared to placebo in women undergoing surgery. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

July 1, 1992Clinical Pharmacology & Therapeutics

Ondansetron is effective in decreasing postoperative nausea and vomiting

Q: What are the key findings of this study?

Intravenous ondansetron significantly increased the rate of complete responders (no emetic episodes or rescue therapy) compared to placebo (58% vs 4%, P<0.001) in women undergoing surgery.

Q: What does this research mean for the field?

Intravenous ondansetron significantly reduces postoperative nausea and vomiting compared to placebo in women undergoing surgery. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

IV ondansetron increases complete response to ~58% versus placebo in women undergoing surgery.

P<0.001
n=50

Why the study?

The efficacy of ondansetron in preventing postoperative nausea and vomiting in surgical patients was studied to address the need for effective prophylaxis.

Does intravenous ondansetron prevent postoperative nausea and vomiting in female surgical patients?

Comparison

Two 8 mg doses of intravenous ondansetron vs two doses of placebo vehicle

Design

Randomized double-blind controlled trial

Follow-up

24 hours

Authors

MDMark DershwitzUniversity of Massachusetts Chan Medical School CRCarl E. RosowHarvard University PBP. M. Di BiaseResearch Triangle Park Foundation

Discussion

Member takes

Overview

Supports routine IV ondansetron use for PONV prophylaxis in women undergoing surgery; confirms efficacy versus placebo in this RCT.

Study Design

Type

RCT (n=50)

Blinding

Double-blind

Randomization

randomized

Structured PICO

Does intravenous ondansetron prevent postoperative nausea and vomiting in female surgical patients?

Population

50 women undergoing surgery with general anesthesia, evaluated for postoperative nausea and vomiting over 24 hours.

Intervention

Ondansetron 8 mg intravenous, two doses (first given just before general anesthesia induction, second 8 hours later)

Comparator

Placebo vehicle, two doses (first given just before general anesthesia induction, second 8 hours later)

Outcome

Number of emetic episodes and subjective nausea scores (0 to 10 scale) during the first 24 postoperative hourspatient reported

Main Result

Absolute Event Rate: 58% vs 4%

p-value: p=<0.001

Intravenous ondansetron is highly effective in preventing postoperative nausea and vomiting in female surgical patients.

Cite This Study

Dershwitz et al. (1992) conducted an RCT in Postoperative nausea and vomiting (n=50). Ondansetron vs. Placebo was evaluated on Complete responders (no emetic episodes and no rescue therapy) (p=<0.001). Intravenous ondansetron significantly increased the rate of complete responders (no emetic episodes or rescue therapy) compared to placebo (58% vs 4%, P<0.001) in women undergoing surgery.

synapsesocial.com/papers/6aacdc37defaaedc0aaab44c https://doi.org/10.1038/clpt.1992.107

View Full Paper

Ask AI

Bookmark

July 1, 1992Clinical Pharmacology & Therapeutics

Ondansetron is effective in decreasing postoperative nausea and vomiting

View Full Paper

Ask AI

Bookmark

Key result

IV ondansetron increases complete response to ~58% versus placebo in women undergoing surgery.

P<0.001
n=50

Why the study?

The efficacy of ondansetron in preventing postoperative nausea and vomiting in surgical patients was studied to address the need for effective prophylaxis.

Does intravenous ondansetron prevent postoperative nausea and vomiting in female surgical patients?

Comparison

Two 8 mg doses of intravenous ondansetron vs two doses of placebo vehicle

Design

Randomized double-blind controlled trial

Follow-up

24 hours

Authors

MDMark DershwitzUniversity of Massachusetts Chan Medical School CRCarl E. RosowHarvard University PBP. M. Di BiaseResearch Triangle Park Foundation

Discussion

Member takes

Overview

Supports routine IV ondansetron use for PONV prophylaxis in women undergoing surgery; confirms efficacy versus placebo in this RCT.

Study Design

Type

RCT (n=50)

Blinding

Double-blind

Randomization

randomized

Structured PICO

Does intravenous ondansetron prevent postoperative nausea and vomiting in female surgical patients?

Population

50 women undergoing surgery with general anesthesia, evaluated for postoperative nausea and vomiting over 24 hours.

Intervention

Ondansetron 8 mg intravenous, two doses (first given just before general anesthesia induction, second 8 hours later)

Comparator

Placebo vehicle, two doses (first given just before general anesthesia induction, second 8 hours later)

Outcome

Number of emetic episodes and subjective nausea scores (0 to 10 scale) during the first 24 postoperative hourspatient reported

Main Result

Absolute Event Rate: 58% vs 4%

p-value: p=<0.001

Intravenous ondansetron is highly effective in preventing postoperative nausea and vomiting in female surgical patients.

Cite This Study

synapsesocial.com/papers/6aacdc37defaaedc0aaab44c https://doi.org/10.1038/clpt.1992.107

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark